Anti-CD112R Antibody CDR Combinations for Checkpoint Blocking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an urgent need for high-quality anti-CD112R antibodies that can bind human CD112R with high affinity and inhibit its interaction with CD112, thereby enhancing immune cell activation and anti-tumor responses.

Innovation Solution

Development of antibodies and antigen-binding fragments that specifically target human CD112R, comprising various combinations of heavy and light chain complementarity-determining regions (CDRs) as listed in SEQ ID NOs: 430-650, which inhibit the binding of CD112R to CD112 and stimulate CD8 T cells to kill tumor cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If prior art anti-CD112R antibodies are used, then some binding activity is achieved, but high affinity binding to human/cynomolgus monkey CD112R and effective inhibition of CD112R-CD112 interaction is not sufficient

Engineering Contradiction:

Improvebinding affinity and inhibitory efficacyVSAvoidantibody quality consistency

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent systematically optimized antibody parameters including CDR sequence composition, amino acid substitutions, and structural configurations to achieve high affinity binding. Multiple antibody variants were generated with specific CDR sequences (SEQ ID NOs: 430-650) to fine-tune binding characteristics and inhibitory efficacy against CD112R-CD112 interaction.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite antibody structures combining specific heavy chain CDRs (HCDR1, HCDR2, HCDR3) and light chain CDRs (LCDR1, LCDR2, LCDR3) from different sources or configurations to create antibodies with enhanced and balanced properties for both binding affinity and inhibitory function.

Inventive Principle:

Principle #40Composite materials

2Reliability

If anti-CD112R antibodies are administered to block CD112R-CD112 interaction, then immune cell activation is enhanced, but the complexity of identifying optimal antibody variants increases

Engineering Contradiction:

Improveimmune response enhancementVSAvoidantibody variant identification

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent divides the antibody structure into distinct CDR regions (HCDR1-3 and LCDR1-3) that can be independently optimized and combined. This segmentation allows systematic evaluation of different CDR combinations to identify variants with optimal balance between binding affinity and inhibitory efficacy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent develops a family of antibody variants sharing common structural frameworks and CDR patterns that can be used across different applications (binding assays, blocking experiments, therapeutic development), reducing the need to develop entirely new antibodies for each purpose.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP4644419A1Antibody targeting CD112r or antigen-binding fragment thereof and use thereof

Publication Date: 2025.11.05 HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD

AI summary

The present application relates to an anti-CD112R antibody or an antigen-binding fragment thereof, and a preparation method therefor and the use thereof. The present invention further relates to the therapeutic and diagnostic uses of the antibodies and antibody fragments.